Senzime AB (publ) (FRA:6YC)

Market Cap	52.72M -44.2%
Revenue (ttm)	9.28M +27.4%
Net Income	-10.14M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,000
Open	0.3120
Previous Close	0.3215
Day's Range	0.3120 - 0.3235
52-Week Range	0.2885 - 0.6700
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Senzime AB

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz ...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1999
• Employees: 59
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6YC

Financial Performance

In 2025, Senzime AB's revenue was 104.02 million, an increase of 77.89% compared to the previous year's 58.48 million. Losses were -137.42 million, 15.7% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error